Expression and clinical significance of SLFN11, a determinant of anticancer drug sensitivity in multiple myeloma.

Research Project

Project/Area Number	25K11676
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 54010:Hematology and medical oncology-related
Research Institution	Jikei University School of Medicine
Principal Investigator	荒川泰弘東京慈恵会医科大学, 医学部, 准教授 (80349547)
Co-Investigator(Kenkyū-buntansha)	鈴木一史東京慈恵会医科大学, 医学部, 講師 (70643336)
Project Period (FY)	2025-04-01 – 2028-03-31
Project Status	Granted (Fiscal Year 2025)
Budget Amount *help	¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000) Fiscal Year 2027: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000) Fiscal Year 2026: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000) Fiscal Year 2025: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords	多発性骨髄腫
Outline of Research at the Start	(a) 多発性骨髄腫の病型、臨床病理学的因子とSLFN11の発現との関連を評価する。 (b) SLFN11の発現と化学療法の効果との相関を検証する。 (c) 初発時と比較して、化学療法後や再発時のSLFN11の発現に変化があるか比較する。